TokenPost·
SELLAS Shares Rise 20% as It Expects Leukemia Trial Results This Month
The company expects results from its Phase 3 REGAL study of galinpepimut-S. Its quarterly loss per share was in line with Wall Street expectations.
More news
- TokenPostBurry Adds Nasdaq-100 Puts and Deepens Bearish SMH Position
- TokenPostUltra (UOS) Falls 9.13% in 15 Minutes as Daily Loss Hits 28.16%
- TokenPostPoste Italiane’s Management-View Revenue Rises 5.4% in Nine Months
- TokenPostWienerberger Q3 Revenue Rises About 8% as Operating EBITDA Falls
- TokenPostBitcoin Liquidation Map Shows $276 Million in Long-Side Intensity Below $67,000
- TokenPostHireQuest Posts High-Teens System-Wide Sales Growth in Early Q4